Blog
RSS FeedPosted by Michael Wonder on 12 Mar 2026
Health ministry cautious on timing of generic drug price cuts, reaffirms ‘no-exception’ principle
11 March 2026 - Amid mounting opposition from the pharmaceutical industry over the government's proposed “drug pricing system improvement plan,” ...
Posted by Michael Wonder on 06 Mar 2026
Roche's Columvi, Takeda's Fruzaqla pass first review for Korea insurance coverage
5 March 2026 - Roche's DLBCL treatment Columvi (glofitamab) and Takeda's metastatic colorectal cancer treatment Fruzaqla (fruquintinib) have cleared the ...
Posted by Michael Wonder on 04 Mar 2026
J&J Korea receives reimbursement for Balversa in urothelial carcinoma
3 March 2026 - Johnson & Johnson Innovative Medicine Korea said it received reimbursement for Balversa (erdafitinib), a treatment for ...
Posted by Michael Wonder on 03 Mar 2026
Xpovio receives reimbursement approval in South Korea for a second multiple myeloma indication
1 March 2026 - Antengene announced that South Korea's National Health Insurance Service has approved the reimbursement of Xpovio (selinexor) in ...
Posted by Michael Wonder on 03 Mar 2026
Expanded reimbursement for Roche Korea’s Evrysdi broadens access for SMA patients
3 March 2026 - Roche Korea said the expanded health insurance coverage and updated reimbursement criteria for the oral spinal ...
Posted by Michael Wonder on 18 Feb 2026
Novo’s Ozempic wins reimbursement in Korea but strict criteria limit early access
12 February 2026 - The entry of Novo Nordisk's GLP-1 receptor agonist Ozempic (semaglutide) into the Korean reimbursement market marks ...
Posted by Michael Wonder on 12 Feb 2026
Pharma group warns drug price cuts threaten industry investment
10 February 2026 - KPBMA demands postponement, impact assessments, and policy dialogue to protect R&D and health security amid pricing reforms. ...
Posted by Michael Wonder on 27 Jan 2026
Novo's Ozempic to gain insurance coverage for diabetes in Korea from February under new criteria
23 January 2026 - Starting in February, Korea's national health insurance will cover Novo Nordisk's Ozempic pre-filled pen, which contains ...
Posted by Michael Wonder on 21 Jan 2026
Truqap faces double barrier in Korea as NGS and drug reimbursement lag
20 January 2026 - As demand for next generation sequencing screening rises, a new drug for metastatic breast cancer faces ...
Posted by Michael Wonder on 18 Jan 2026
Darzalex clears HIRA hurdle for AL amyloidosis reimbursement in Korea
16 January 2026 - The treatment barriers will likely be significantly lowered for patients with rare diseases in Korea, such ...
Posted by Michael Wonder on 07 Jan 2026
Korea’s next homegrown drug could be a first local CAR-T as payer keeps widening access
6 January 2026 - Korea spent 2025 doing something it has not always been quick to do: it paid for ...
Posted by Michael Wonder on 04 Jan 2026
Bayer Korea's Eylea pre-filled syringe 8 mg to receive health insurance coverage
30 December 2025 - Bayer Korea announced that its Eylea pre-filled syringe 8 mg will be covered by health insurance ...
Posted by Michael Wonder on 04 Jan 2026
GC Biopharma’s Livmarli listed for national health insurance coverage for Alagille syndrome
2 January 2026 - GC Biopharma said Livmarli (maralixibat chloride), a treatment for Alagille syndrome, has been officially listed on ...
Posted by Michael Wonder on 28 Dec 2025
Drug makers push back against government’s generic price cut plan
28 December 2025 - Pharma industry warns lower generic prices will curb R&D, health officials cite unchanged pricing since 2012. ...
Posted by Michael Wonder on 25 Dec 2025
Korea to expand Keytruda reimbursement to 11 new cancer uses starting 2026
24 December 2025 - Korea’s national health insurance program will broaden reimbursement for MSD’s blockbuster PD-1 inhibitor Keytruda in a ...